Skyhawk Therapeutics’ Post

Following a truly insight-rich discussion last week with Nicola McCarthy and Namshik Han of the Milner Therapeutics Institute and Biorelate's CSO Ben Sidders, you can now access the recorded webinar >> https://lnkd.in/eZsq-25A #drugdiscovery #artificialintelligence #bioinformatics

Building causal hypotheses in drug discovery 🎥🤔 If you missed last week's panel discussion with our own Nicola McCarthy and Namshik Han, and Biorelate's Ben Sidders and Daniel Jamieson, you can now view the recording online! Where are the opportunities to use AI and data driven approaches to create more robust models for developing actionable hypotheses? How can biopharma make better use of data for developing mechanistic rationales that will improve drug discovery outcomes for drug developers and patients? Join the discussion by clicking here 👉 https://lnkd.in/eZsq-25A

Longitude portfolio company Vera Therapeutics, Inc. has shown the effect of atacicept on kidney function in patients with immunoglobulin A nephropathy (IgAN) persists out to 96 weeks. The durability of the effects seen in the phase 2b trial led Evercore ISI analysts to say “this feels like a ‘functional cure’," reports Nick Paul Taylor in Fierce Biotech. Read more about atacicept's data at https://lnkd.in/eVZxWxdz #Biotech

Good news for Solvonis Therapeutics plc after a positive pre-IND meeting with the US Food and Drug Administration has provided a clear path forward for advancing its drug for alcohol use disorder to the next phase of clinical testing. The drug, AWKN-002, is an oral thin film formulation of esketamine. Solvonis plans to acquire Awakn Life Sciences, the company behind the drug. hVIVO has secured a £2.7 million contract to support a US biotech firm's phase II trial for a new influenza drug. It's the largest standalone laboratory contract to date for hVIVO. The hLAB facility will be the sole virology lab for the international study, which involves 5,000 participants. Ilika plc has reported 'significant progress' with its Stereax and Goliath battery lines. CEO Graeme Purdy highlighted the developments during the announcement of the company's first-half results. Watch at #Proactive #ProactiveInvestors http://ow.ly/7ISS105Xppy

Stop by and check out Vector Labs newest and greatest tomorrow at The Cove! Let’s talk about our new dPEG Linker platform for BioDesign of Bioconjugate Therapeutics. #vectorlabs #ADCs #dPEG #BioDesign

🌴💸 A tropical-themed Financial Friday update for you and I can only apologise for my terrible taste in clothing, luckily the positive investment rounds this week should distract you from that (alternatively just listen to the audio!) A comprehensive overview is in my video but a brief rundown of the funding this week is below: 💰 Zenas BioPharma - $200 million series C 💵 Bluejay Therapeutics - $182 million series C 🤑 Attovia Therapeutics - $105 million series B 💲 Aardvark Therapeutics - $85 million series C 💳 Latus Bio - $54 million launch #financialfriday #biotechinvestment #vcfunding

#DYK: ~75% of disease-causing targets are located inside cells and most are still considered inaccessible? We believe we have discovered the solution to the fundamental challenges of intracellular therapeutics. Our proprietary EEV™ platform is designed to engage targets previously considered inaccessible and undruggable and has the potential to translate into substantial improvements in efficacy, safety and tolerability of future medicines. Learn more about our EEV™-therapeutics: https://lnkd.in/dcFuBP5F #Biotech #Oligonucleotides #EndosomalEscape

BCBN Feed: Aviceda raises $207M series C to take geographic atrophy drug through phase 3 https://lnkd.in/g89UGfYs Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 readout this year for its lead eye disease drug. The round was co-led by the healthcare funds Omega Funds and TCGX, with participation from other investors such as Enavate Sciences,... ... [...]

Leading Through Biotech's Perfect Storm: Lessons From The Front Lines https://lnkd.in/e2AA58mn - By Erik van den Berg, CEO, Memo Therapeutics AG

🚀 The good news keeps rolling! Keltic Pharma, a spin-out from the University of Glasgow, has been awarded a SMART Grant by Innovate UK! 🚀 Founded by Andrew Tobin, Andrew Jamieson, and Graeme Milligan, Keltic Pharma Therapeutics are thrilled to receive this recognition and support for our work on the PEPSMOL© Discovery Platform. This innovative approach targets previously hard-to-drug G protein-coupled receptors (GPCRs), with an initial focus on the FFA4 receptor. With this funding, we'll be advancing our development of synthetic biologics—a new class of molecules that blend the best properties of small molecules and biologics like antibodies. Our initial focus is on tackling severe asthma, a condition unresponsive to current treatments, by developing inhaled agents to normalise lung function and reduce inflammation. The SMART Grant enables us to expand our team in Glasgow, validate the platform, and drive forward our mission to bring new, effective treatments to patients and push the boundaries of biotech innovation in the UK. Follow us for more updates as we move forward on this exciting journey! 🌟 #SMARTGrant #InnovateUK #Biotech #Innovation #DrugDiscovery #Asthma #GPCR